Form 4 for KNSA Kiniksa Pharmaceuticals International, plc

Accepted 2026-04-08 16:34:47 ET · period of report 2026-04-06 · accession 0001384243-26-000008 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DT	2026-04-08 16:34	2026-04-06	KNSA	Quart Barry D	Dir	M - OptEx	$14.33	+6,901	19.4K	+55%	+$98.9K
DT	2026-04-08 16:34	2026-04-06	KNSA	Quart Barry D	Dir	S - Sale+OE	$50.00	-6,901	12.5K	-35%	-$345.1K
DT	2026-04-08 16:34	2026-04-06	KNSA	Quart Barry D	Dir	M - OptEx	$0.00	-6,901	26.3K	-21%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Class A Ordinary Share	2026-04-06	M	A	6,901	$14.33	19,447	D	—	—	(F1) This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025.
2	Common	Class A Ordinary Share	2026-04-06	S	D	6,901	$50.00	12,546	D	—	—	(F1) This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $50.00 and $50.015. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3	Derivative	Share Option	2026-04-06	M	D	6,901	$0.00	26,336	D	$14.33 · — to 2031-06-28	6,901 Class A Ordinary Shares	(F1) This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 11, 2025. (F3) The option is fully vested and exercisable.